Universität zu Köln

Schneider, Christian A. and Pfister, Roman (2018). Modern Antidiabetics in Cardiology. Aktuelle Kardiol., 7 (4). S. 286 - 292. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2193-5211

Full text not available from this repository.

Abstract

Diabetes mellitus type 2 leads to a significant reduction in life expectancy of up to 22 years depending on the age and concomitant vascular diseases. Therefore, the ultimate treatment goal should be improvement of prognosis. New medication might be beneficial in this respect. New antidiabetic medication include GLP-1 agonists, DPP-4 inhibitors and SGLT-2 inhibitors. GLP-1 agonist lead to a distinct glucose lowering and is frequently associated with gastrointestinal side effects. GLP-1 agonists and SGLT-2 inhibitors lead to moderate glucose lowering with low side effect profile. Among the modern antidiabetic medication Empagliflozin and Liraglutide are the only medication for which significant reduction of cardiovascular endpoints and total mortality have been demonstrated. Therefore, these drugs should be preferred in the treatment of cardiovascular high risk patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schneider, Christian A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, Roman UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-178192
DOI:	10.1055/a-0655-7407
Journal or Publication Title:	Aktuelle Kardiol.
Volume:	7
Number:	4
Page Range:	S. 286 - 292
Date:	2018
Publisher:	GEORG THIEME VERLAG KG
Place of Publication:	STUTTGART
ISSN:	2193-5211
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PEPTIDE-1 RECEPTOR AGONISTS; CARDIOVASCULAR OUTCOMES; CLINICAL-OUTCOMES; EMPAGLIFLOZIN; LIRAGLUTIDE; ASSOCIATION; INHIBITORS; MORTALITY; RISK Multiple languages Cardiac & Cardiovascular Systems Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/17819